Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229056 | 0.99 | ADORA2A (0.73) | ADORA2AADORA2BKMT2ALMNAMAPT | |
| SCHEMBL3235950 | 0.97 | ADORA2A (0.69) | ADORA2AADORA2BKMT2ALMNAMAPT | |
| SCHEMBL3231972 | 0.86 | ADORA2A (0.54) | ADORA2AADORA2BLMNAMAPTADORA3 | |
| SCHEMBL5453936 | 0.85 | ADORA2A (1.00) | ADORA2AADORA2BKMT2ALMNAADORA3 | |
| SCHEMBL5935758 | 0.84 | ADORA2A (1.00) | ADORA2AADORA2BKMT2ALMNAADORA3 | |
| SCHEMBL8576289 | 0.82 | ADORA3 (0.56) | ADORA2AADORA2BKMT2AADORA3ADORA1 | |
| SCHEMBL3233890 | 0.82 | LMNA (0.80) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL3236970 | 0.82 | ADORA2A (0.49) | ADORA2AADORA2BLMNAMAPTADORA3 | |
| SCHEMBL3227456 | 0.81 | LMNA (0.82) | KMT2ALMNAMAPTADORA3HTT | |
| SCHEMBL3235634 | 0.81 | LMNA (0.78) | LMNAMAPTADORA3HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | ADORA2A 183/4885ADORA2B 130/4885KMT2A 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.